Newswise — Researchers at Nicklaus Children’s Hospital in Miami, Florida have performed the first procedure in a pediatric and young adult brain tumor study. The trial aims to demonstrate feasibility and safety of using focused ultrasound to ablate a variety of benign tumors located in the central part of the brain in ten patients, ages 8 to 22. Left untreated, these tumors often cause seizures, cognitive delays, or other complications as they grow.
The first patient enrolled in the study suffered from debilitating seizures as a result of a hypothalamic hamartoma. After a single focused ultrasound procedure on March 7 using Insightec’s Exablate Neuro system, MRI scans showed complete ablation of the tumor. The patient was able to go home the following day, returned to school days later, and remains seizure-free.
The medical and research team at Nicklaus Children’s consists of Dr. John Ragheb, Director Division of Neurosurgery; Dr. Travis Tierney, neurosurgeon and the trial’s Principal Investigator: Dr. Ian Miller, Director of Epilepsy Program; Dr. Sanjiv Bhatia, neurosurgeon; Dr. Nolan Altman, Director of Radiology; Dr. Prasanna Jayakar, Chairman of Brain Institute; and Dr. Jennifer McCafferty, Director of Research, Miami Children’s Research Institute.
“Any procedure that is the first of its kind is a bit like launching a space shuttle, but we were confident that focused ultrasound is a perfect match for these types of tumors.” says Dr. Travis Tierney. “Nicklaus Children’s is a leader in treating pediatric epilepsy, so to have a new, innovative tool to offer children and families suffering with these seizure-inducing brain tumors is an exciting achievement.”
Traditional treatment options available include anti-epileptic medications or conventional surgery to remove the mass. However, invasive techniques are associated with risks of bleeding, infections, and even developing new neurological problems. Anti-epileptic medications can also have undesirable side effects or may be ineffective for many patients.
”Focused ultrasound offers many benefits over traditional surgery that are particularly important to pediatric patients.” says Focused Ultrasound Foundation’s Chief Medical Officer, Tim Meakem, MD. “It is incisionless, avoids ionizing radiation, offers less risk of infection and disruption of adjacent normal tissue, can be repeated if necessary, and affords minimal downtime from daily activities.”
The study is jointly funded by the Foundation and Nicklaus Children’s Hospital. Insightec is the regulatory sponsor.
“Expanding focused ultrasound’s reach into pediatrics is one of our main goals in 2017,” says Foundation Chairman Neal F. Kassell, MD. “The technology has proven itself safe and effective in ablating tissue in the adult brain for movement disorders, and it is already being investigated for soft tissue tumors and painful bone tumors in younger patients. We look forward to continuing to work with Nicklaus Children’s and other sites worldwide to advance this innovative care for children.”
“Congratulations to the team at Nicklaus Children’s for another first with our MR-guided focused ultrasound technology. We are committed to supporting research efforts such as these that push the boundaries of our technology to treat more and more patients,” said Maurice R. Ferré MD, CEO and Chairman of Insightec.
Patients seeking further information about the study should contact firstname.lastname@example.org.
One class, subependymal giant cell astrocytomas (SEGAs), often cause pediatric epilepsy and can obstruct ventricles, leading to hydrocephalus - a buildup of fluid in the brain. Another central tumor - a hypothalamic hamartoma - can cause gelastic (laughing) seizures and cognitive decline. Other low grade astrocytomas may also be screened.
About Nicklaus Children’s Hospital
Founded in 1950 by Variety Clubs International, Nicklaus Children’s Hospital – part of Miami Children’s Health System – is South Florida’s only licensed specialty hospital exclusively for children, with more than 740 attending physicians and over 220 pediatric subspecialists. The 289-bed hospital is renowned for excellence in all aspects of pediatric medicine with several specialty programs ranked among the best in the nation in 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015 and 2016-17, by U.S. News & World Report. The hospital is also home to the largest pediatric teaching program in the southeastern United States and has been designated an American Nurses Credentialing Center (ANCC) Magnet facility, the nursing profession’s most prestigious institutional honor. For more information, visit nicklauschildrens.org.
INSIGHTEC is the world leader and innovator of MR-guided Focused Ultrasound (MRgFUS). The company’s non-invasive therapy platforms, Exablate and Exablate Neuro, are proven technology based on sound clinical evidence for treating essential tremor, painful bone metastases and uterine fibroids. The company is dedicated to improving patient lives by collaborating with physicians, medical institutions, academic researchers and regulatory bodies around the world. For more information, please visit: www.insightec.com
About the Focused Ultrasound Foundation
The Focused Ultrasound Foundation was created to improve the lives of millions of people worldwide by accelerating the development of focused ultrasound, an early-stage, noninvasive, therapeutic technology with the potential to transform the treatment of many serious medical disorders. The Foundation works to clear the path to global adoption by coordinating and funding research, fostering collaboration, and building awareness among patients and professionals. It is dedicated to ensuring that focused ultrasound finds its place as a mainstream therapy for a range of conditions within years, not decades. Since its establishment in 2006, the Foundation has become the largest non-governmental source of funding for focused ultrasound research. More information can be found at www.fusfoundation.org.